• About Us
    • Our Team
    • Our Work
    • In The News
  • Resources
    • Curated Research Library
    • Popular Articles
    • Legal Beagle Archive
    • The Education Program
    • VCS Vet Research Program
  • Directory of Practitioners
  • Get Involved
    • Become A Sponsor
    • Join Email List
  • Contact
  • SHOP NOW
    • VCS APPAREL
    • PET & PARENT JEWELRY
  • DONATE
  • Members Dashboard
Veterinary Cannabis SocietyVeterinary Cannabis Society
  • About Us
    • Our Team
    • Our Work
    • In The News
  • Resources
    • Curated Research Library
    • Popular Articles
    • Legal Beagle Archive
    • The Education Program
    • VCS Vet Research Program
  • Directory of Practitioners
  • Get Involved
    • Become A Sponsor
    • Join Email List
  • Contact
  • SHOP NOW
    • VCS APPAREL
    • PET & PARENT JEWELRY
  • DONATE
  • Members Dashboard

Pharmacokinetics of cannabidiol following single oral and oral transmucosal administration in dogs

Home Pharmacokinetics of cannabidiol following single oral and oral transmucosal administration in dogs

Curated Research Library

  • Back to Curated Research Library

Pharmacokinetics of cannabidiol following single oral and oral transmucosal administration in dogs

  • By: Giorgia della Rocca, Fabiola Paoletti, Maria Beatrice Conti, corresponding author, Roberta Galarini, Elisabetta Chiaradia, Monica Sforna, Cecilia Dall'Aglio, Angela Polisca, and Alessandra Di Salvo
  • Published On: 6 January, 2023
  • Publication: ncbi.nlm.nih.gov
  • Tags: canine
  • Category: Pharmacokinetics / Pharmacodynamics

Introduction
In the last few years, different formulations containing cannabidiol (CBD) were tested with regard to its efficacy on chronic pain, refractory epilepsy, anxiety, aggressive behavior and atopic dermatitis in dogs. CBD is generally administered orally, but its low bioavailability, probably due to a first-pass metabolism, represents a great limitation. The aim of this study was to evaluate if CBD bioavailability increases after oral transmucosal administration (OTM) compared to oral treatment.

Methods
Twelve dogs diagnosed with mild chronic pain were enrolled in the study and treated once orally or OTM (6 dogs/group) with a pure CBD in oil formulation at a dosing rate of 1 mg/kg b.w. At prefixed time points, blood samples were collected to define CBD plasma concentrations vs. time profiles, and the main pharmacokinetics parameters were obtained by non-compartmental model.

Results
CBD Cmax, Tmax, terminal half-life and AUC0 − t were 206.77 ± 167 and 200.33 ± 158.33 ng/mL, 2.17 ± 0.98 and 1.92 ± 1.11 h, 2.67 ± 0.53 and 2.62 ± 0.64 h, 647.51 ± 453.17, and 536.05 ± 370.21 h*ng/mL, following oral and OTM administration, respectively. No significant difference in pharmacokinetic parameters were observed between treatments.

Discussion
The OTM administration did not increase cannabidiol bioavailability compared to oral treatment. The almost perfectly superimposable mean plasma concentrations of cannabidiol following the two treatments suggests that CBD is not able to be adsorbed by the oral mucosa or that its absorption is very scarce, and that CBD is swallowed and absorbed in the gastrointestinal tract.

Click Here to Access Article
  • Back to Curated Research Library
Search

Our Mission is to create lasting solutions that ensure the safe use of cannabis in pets through education, advocacy, and promoting product standards.

Our Vision is an educated and empowered global veterinary medical cannabis community.

  • About Us
  • Our Work
  • Get Involved
  • Contact Us
  • Donate

Email:
Click here to email us

Florida Mailing Address
7901 4th St. North, Suite 4404
St. Petersburg, FL 33702

Veterinary Cannabis Society is a nonprofit, 501(c)(3) organization in the United States. Tax ID #85-0986090

Veterinary Cannabis Society does not endorse any specific products.

© 2025 · Veterinary Cannabis Society

  • Terms of Use
  • Privacy Policy
  • State Notices
  • Contact